When zooming in on different clinical subgroups (Table 4), we observed different hazard ratios for patients with POLE-mutated tumors with respect to sex, age, grade, and location of tumor, all of which were, again, not statistically significantly different. The gene discussed is POLE; the disease is neoplasm.